

EXPRESS MAIL CERTIFICATE

Date 10/29/99 Label No. 595862917

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print) D B Peck Signature D B PeckJC490 U.S. PTO
09/429832
10/29/99

File No. 0646/1D205-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ramesh A. BHAT, et al.

For: NOVEL HUMAN ESTROGEN RECEPTOR B

CONTINUING APPLICATION

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

This is a request for filing under 37 C.F.R. 1.53(b) of a:

☐ Continuation ☒ Divisional

application of the following pending prior application:

Serial No. 08/906,365 Filed: August 5, 1997

Of: Ramesh A. BHAT, et al.

For: NOVEL HUMAN ESTROGEN RECEPTOR B

Examiner: N. Basi Group: 1646

- i. Enclosed is a copy of the prior application as originally filed (along with a copy of the original Declaration). No amendments identified in the declaration for this prior application introduced new matter. Please use this copy as the application and declaration for the present case.

- ii. The filing fee is calculated below:

CLAIMS AS FILED, AFTER ACCOMPANYING AMENDMENT

| | Claims on File | Number Extra | Rate |
|--|---------------------|--------------|-----------|
| Basic Fee | | | \$ 760.00 |
| Total Claims | 8 - 20 = | x \$18 | \$ |
| Independent Claims | 3 - 3 = | x \$78 | \$ |
| If Multiple Dependent Claims Are Present, Add \$260.00 | | | \$ |
| Total Filing Fee | | | \$ 760.00 |
| For Small Entity (half of preceding total)* | | | \$ |

*No. 9 below must be checked to claim this reduction.

- iii. A check in the amount of \$760.00 is enclosed.
- iv. ☒ Cancel claims 1-16.
- v. ☒ Amend the specification by inserting before the first line the sentence (check one and fill in):

"This is a ☐ continuation, ☒ division, of application Serial No. 08/906,365, filed August 5, 1997. Each of these prior applications is hereby incorporated herein by reference, in its entirety."

- vi. ☒ The prior application is assigned to: American Home Products Corporation
- vii. ☐ A Preliminary Amendment is also enclosed.
- viii. ☒ Informal Drawings are filed herewith.

ix. ☐ A verified statement claiming small entity status
(check one):

☐ was filed in parent application or
☐ is enclosed.

x. ☐ Priority is claimed from

Country:

Number:

Date:

The priority document

☐ was filed in the prior application
☐ is enclosed.

xi. The Assignment


[X] was recorded at Reel 9062 Frame 0222 on March 18, 1998
☐ is enclosed.

xii.

[X] Associate Power of Attorney naming the undersigned as
applicants' attorney for this application.

Dated: October 29, 1999

Respectfully submitted,



Paul F. Fehlner, Ph.D.

Reg. No. 35,135

Attorney for Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022
212-527-7700

Date 8/5/97 Label No. EM016718307

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

0646/0D205

D.B. Beck
Sender (Print)D.B. Beck
Addressee (Print)NOVEL HUMAN ESTROGEN RECEPTOR- β Field of the Invention

This invention pertains to DNA encoding a novel human estrogen receptor- β (hER β), hER β polypeptides, and methods for expressing and isolating hER β . The invention also pertains to methods for using hER β to identify coactivators and inhibitors as well as tissue-specific estrogens.

Background of the Invention

The physiological response to steroid hormones is mediated by specific interactions of steroids with nuclear receptors, which are ligand-activated transcription factors that regulate the expression of target genes by binding to specific DNA response elements. These receptors comprise (in an aminoterminal-to-carboxyterminal direction) a hypervariable aminoterminal domain that contributes to the transactivation function; a highly conserved DNA-binding domain responsible for receptor dimerization and specific DNA binding; and a carboxyterminal domain involved in ligand-binding, nuclear localization, and ligand-dependent transactivation.

Recently, cDNA was cloned from rat prostate and was shown to have significant homology to a previously isolated rat estrogen receptor cDNA. Kuiper et al., *Proc.Natl.Acad.Sci.USA* 93:5925, 1996. This receptor was designated ER β to distinguish it from a previously cloned receptor, ER α . Rat ER β was shown to be expressed in the

prostate, testes, ovary, and thymus, in contrast to ER α , which is most highly expressed in the uterus, breast, liver, and pituitary.

A human ER β homologue having the aminoterminal sequence Gly-Tyr-Ser has been reported. Mosselman et al., *FEBS Letts.* **392**:49, 1996. This reported sequence lacks an initiator methionine, however; therefore, the complete aminoterminal sequence could not be determined. Thus, the full-length human gene remained unknown and an accurate picture of the molecular determinants of the transactivation function of authentic hER β could not be obtained.

10 Summary of the Invention

The present invention provides nucleic acids encoding a full-length human estrogen receptor- β (hER β_L). The nucleic acid sequence of hER β_L , which is depicted in Figure 3, SEQ ID NO:1, encodes a receptor having the amino acid sequence depicted in Figure 4, SEQ ID NO:2. hER β_L according to the present invention contains 45 amino acids at its aminotermus which were not previously known. These amino acids are believed to contribute to the transcription activation function of the receptor.

hER β_L is selectively expressed in the thymus, spleen, ovary, and testes. Accordingly, hER β can be used to identify co-activator proteins that are involved in estrogen-regulated gene expression, as well to identify tissue-selective estrogens.

The present invention provides isolated polypeptides having the sequence of SEQ ID NO:2 and function-conservative variants thereof which exhibit estrogen-regulated transcriptional activation activity. In a related aspect, the invention encompasses isolated peptides derived from hER β comprising a sequence corresponding to amino acids 1-45 of

SEQ ID NO:2 and function-conservative variants thereof, as explained above. It is believed that this sequence provides at least part of the transactivation function.

The present invention also provides isolated nucleic acids encoding hER β _L and hER β _L-derived peptides, including the nucleic acid sequence depicted in Figure 3, SEQ ID NO:1 and subfragments thereof encoding peptides which comprise amino acids 1-45, as well as sequence-conservative and function-conservative variants thereof. Also encompassed by the invention are DNA vectors comprising an hER β _L-encoding sequence operably linked to a transcription regulatory element and cells comprising these vectors. Methods for producing hER β _L-derived polypeptides include incubating a cell comprising an hER β _L-encoding expression vector under conditions that permit expression of one or more hER β polypeptides. The methods further include: (a) harvesting the cells to produce a cell fraction and a medium fraction; and (b) recovering the polypeptide(s) from the cell fraction, medium fraction, or both.

In another aspect, the invention provides methods for identifying hER β -interactive compounds, including agonists, antagonists, and co-activator proteins. In one embodiment, the method includes:

(a) contacting purified hER β with a labeled ligand in the presence of test compounds, to form test reactions, and in the absence of test compounds, to form control reactions;

(b) incubating the test and control reactions under appropriate conditions to achieve specific binding of the labelled ligand to hER β ;

(c) determining the level of binding of the labeled ligand to hER β in said test and control cultures; and

(d) identifying as a hER β -interactive compound any compound that reduces the binding of the labeled ligand to hER β .

Brief Description of the Drawings

5 Figure 1 is a schematic illustration of the oligonucleotides used for PCR amplification of human estrogen receptor- β (hER β_L) cDNA.

Figure 2 is a schematic illustration of the pcDNA3 plasmid containing hER β_L cDNA.

10 Figure 3 is an illustration of the full-length cDNA sequence encoding human estrogen receptor- β (hER β_L) (SEQ ID NO:1).

Figure 4 is an illustration of the predicted amino acid sequence of the hER β polypeptide (SEQ ID NO:2). The first 45 (previously unknown) amino acids are underlined.

15 Figure 5 is a photographic illustration of an autoradiogram of a 10% SDS-polyacrylamide gel in which hER β *in vitro* translation products are resolved. Lane 1, hER β_T ; lane 2, hER β_L produced from a vector encoding a synthetic translation initiation site; lane 3, hER β_L produced from a vector encoding the natural hER β translation initiation sequences.

20 Figure 6A is a graphic illustration of the transcriptional activation capacity of full-length hER β (hER β_L) and truncated hER β (hER β_T) expressed in HepG2 cells. Cells were transfected with either hER β_L or hER β_T and co-transfected with a luciferase reporter plasmid containing an estrogen response element (ERE) (ERE.TK.LUC) and a control β -galactosidase plasmid. Cells were incubated in the absence or presence of estradiol, after which luciferase activity was measured and normalized to β -galactosidase activity. Figure 6B is a graphic

illustration of luciferase activity in HepG2 cells transfected with either hER β_L or hER β_T and co-transfected with a luciferase reporter plasmid lacking an ERE (TK.LUC)

Figure 7A is a graphic illustration of the effect of estradiol stimulation of full-length hER β (hER β_L) and truncated hER β (hER β_T) on NFkB activation in HepG2 cells. Cells were transfected with either hER β_L or hER β_T and co-transfected with a luciferase reporter plasmid containing three copies of an NFkB binding site (3X-NFkB TK.LUC) and a control β -galactosidase plasmid. Cells were stimulated with interleukin-1 β and incubated in the absence or presence of estradiol, after which luciferase activity was measured and normalized to β -galactosidase activity. Figure 7B is a graphic illustration of luciferase activity in cells transfected with either hER β_L or hER β_T and co-transfected with a luciferase reporter plasmid lacking an NFkB binding site (TK.LUC).

Figure 8 is a graphic illustration of the transcriptional activation capacity of full-length hER β (hER β_L) and truncated hER β (hER β_T) expressed in HAECT-1 human endothelial cells. Cells were transfected with either hER β_L or hER β_T and co-transfected with a luciferase reporter plasmid containing an ERE (ERE.TK.LUC) or one lacking an ERE (TK.LUC). Cells were incubated in the absence or presence of estradiol, after which luciferase activity was measured. ERE TK.LUC values were normalized to TK.LUC values and are presented as mean \pm S.E. (n=4).

Figure 9 is a graphic illustration of the effect of increasing doses of estrogens (17- β estradiol or genistein) on the transcriptional activation capacity of full-length hER β (hER β_L) and truncated hER β (hER β_T) expressed in *S. cerevisiae*. Cells were transformed with either hER β_L or hER β_T and co-transformed with a β -galactosidase reporter plasmid

containing an ERE. Transformed cells were treated with estrogens for 3h and assayed for β -galactosidase activity.

Detailed Description of the Invention

5 Human estrogen receptor- β (hereinafter, hER β) comprises aminoterminal amino acid residues not previously known. The present invention encompasses isolated, purified, nucleic acids encoding authentic full-length hER β of 530 amino acid residues and fragments thereof which include nucleic acids encoding amino acids 1-45 of hER β . The invention also encompasses isolated, purified, polypeptides comprising hER β and peptides derived
10 therefrom, particularly peptides which include residues 1-45 of hER β . The invention also provides expression systems in which transcriptionally active hER β or fragments derived therefrom can be produced, as well as screening methods for identifying hER β agonists and antagonists (including tissue-specific estrogens and anti-estrogens) as well as hER β co-activators and inhibitors.

15

Isolation and Characterization of the Gene Encoding hER β

The present inventors have isolated the cDNA encoding hER β using the methods outlined below. Human testis Poly A+ RNA (1 μ g, Clontech, Palo Alto CA) was mixed with 0.5 μ g oligo dT primer (GIBCO-BRL, Gaithersburg MD) in a total volume of 10
20 μ l. The mixture was heated at 70°C for 10 minutes, and, after cooling on ice, was supplemented with 500 μ M of each deoxynucleoside triphosphate, 1X cDNA synthesis buffer, and 10 mM DTT to a final reaction volume of 20 μ l. The mixture was incubated at 42°C for 2.5 minutes and then supplemented with 1-2 units reverse transcriptase (GIBCO-BRL,

Gaithersburg MD), after which it was incubated at 45°C for 30 minutes and 50°C for 5 minutes. One-tenth of this mixture (approximately 2 μ l) containing the cDNA template was then used in PCR amplification of hER β using forward and reverse primers as described below.

- 5 Alignment of the known rat ER β sequence (Kuiper et al., *Proc.Natl.Acad.Sci.USA* **93**:5925, 1996) with that of a human homologue (Mosselman et al., *FEBS Letts.* **392**:49, 1996) suggested that the human sequence lacked at least the ultimate and penultimate residues at its aminotermminus, as shown below:

Rat: MTFYSPAVMNYS . . .

10 Human: - - GYSPAVMNYS . . .

Based on this information, PCR primers were designed that supplement the human sequence with the two missing aminoterminal residues M and T and with an artificial Kozak translation initiation sequence. The forward primer, having the sequence

5'-GGAAGCTTGTCGACCATCATGACCGGCTATAGCCCTGCTGTGATG-3'

- 15 and a reverse primer, having the sequence

5'-GGATCTAGAGTCGACGCGTCACTGAGACTGAGGGTTCTGG-3'

were used to amplify hER β sequences in a reaction containing the following components:

2 μ l of the cDNA template described above; 1X PCR buffer; 200 μ M of each deoxynucleoside triphosphate, 2 units of hot tab polymerase (Amersham, Arlington Heights
20 IL), and 1 μ g of each of the forward and reverse primers. The reaction mixture was heated to 95°C for 2 minutes, annealed at 52°C for 1 minute, and amplified using 36 cycles of 72°C for 1.5 minutes.

A fragment of approximately 1500 bp in length was produced. The fragment digested with *Hind*III and *Xba*I (which cleave at sites present in the forward and reverse primer sequences, respectively, but not in the main body of the amplified cDNA sequence) and cloned into the corresponding sites of the pcDNA3 expression vector (Invitrogen, Carlsbad CA). This asymmetric cloning strategy places the 5' end of hER β cDNA under the control of the viral CMV promoter in pcDNA3 (Figures 1 and 2). Several insert-containing pcDNA3 clones were identified. Plasmid DNA was prepared from three clones using a plasmid purification kit (Qiagen, Santa Clarita CA) and their insert sequences were determined by the dideoxy termination method. One clone (designated R61010-2.24 or Clone 3) was found to contain an insert with a nucleotide sequence identical to the published hER β sequence (Mosselman et al., *FEBS Letts.* **392**:49, 1996) and had the following 5' end structure:

M T G Y . . .
CCATC ATG ACC GGC TAT . . .

This clone was designated "truncated hER β " or hER β _T.

To verify the aminoterminal and upstream sequence of human hER β , two independent approaches were taken, as described below.

(1) 10 μ l of a human ovary 5'-Stretch cDNA library (Clontech, Palo Alto CA) was mixed with 50 μ l of 1X K solution (1X PCR Buffer (GIBCO-BRL, Gaithersburg MD), 2.5 mM MgCl₂, 0.5% Tween-20, 100 μ g/ml Proteinase K), and the reaction mixture was incubated at 56°C for 2 hours, then at 99°C for 10 minutes. 5 μ l of this reaction mixture were then used as template in a nested PCR reaction. For the first round, the forward primer (pDR2 sequencing primer, Clontech, Palo Alto CA) had the sequence 5'-

CTGGTAAGTTTAGTCTTTTGTGTC-3', and the reverse primer (hER β -specific, designated oligo #12908) had the sequence 5'-GCTTCACACCAAGGACTCTTTTGAG-3'. The reaction contained 1X KlenTaq PCR reaction buffer (40 mM Tricine-KOH, 15 mM KOAc, 3.5 mM Mg(OAc)₂, 75 μ g/ml bovine serum albumin); 0.2 mM of each dNTP; 0.2 μ M of each of the above primers, and 1 unit of KlenTaq Polymerase Mix (Clontech, Palo Alto CA). Touchdown PCR conditions were as follows: 5 cycles of 94°C for 2 seconds and 72°C for 4 minutes, followed by 30 cycles of 94°C for 2 seconds and 67°C for 3 minutes.

Excess nucleotides and primers were removed from first round PCR reactions by purification over Wizard PCR columns (Promega, Madison WI). A second-round PCR reaction was then performed using 2 μ l of the purified first-round reaction mixture. For the second round, the forward primer was the pDR2 sequencing primer shown above, and the reverse primer had the sequence 5'-GTTGGCCACAACACATTTGGGCTTGT-3' (hER β -specific, designated oligo #13871). The PCR reaction and cycling conditions were identical to those employed in the first round. The products were cloned into pCR2.1 (Invitrogen) and three resulting clones were sequenced. All three clones (designated L1, L2, and L3) contained hER β inserts of different lengths, all of which were homologous to hER β and to each other.

(2) A Marathon Ready thymus cDNA kit (Clontech) for 5' rapid amplification of cDNA ends (RACE) was also used to isolated hER β 5' clones. In the first round of a nested PCR reaction, 5 μ l of human thymus Marathon-ready cDNA (Clontech) was used as template. The forward primer had the sequence 5'-CCATCCTAATACGACTCACTATAGGGC-3' (Adaptor primer 1, Clontech), and the reverse primer had the sequence 5'-GCTTCACACCAAGGACTCTTTTGAG-3' (hER β -specific,

designated oligo #12908). The PCR reaction and cycling conditions were identical to those described in (1) above.

Excess nucleotides and primers were removed from the first round PCR reactions by purification over Wizard PCR columns (Promega). A second round PCR reaction was performed using 2 μ l of the purified first round reaction. For the second round, the forward primer had the sequence 5'-ACTCACTATAGGGCTCGAGCGGC-3' (nested adaptor primer 2, Clontech), and the reverse primer had the sequence 5'-GTTGGCCACAACACATTTGGGCTTGT-3' (hER β -specific, designated oligo #13871). The second round PCR reaction and cycling conditions were identical to those employed in the first round. The products were cloned into the pCR2.1 vector and two clones were sequenced. The two clones contain insert sequences of different lengths that are homologous to hER β , to each other, and to the sequences isolated from a human ovary cDNA library as described above.

All of the hER β sequences isolated by methods (1) and (2) above contained 110 nucleotides corresponding to hER β_T sequences, as well as 228 additional nucleotides at the 5' end (Figure 3).

The hER β cDNA sequence determined from these clones contained several important differences from the previously known human sequence. First, the third amino acid of the previous sequence was found to be F and not G (see above). Second, the methionine residue at the aminoterminal of the previous sequence was found not to be the initiator (i.e., true aminoterminal) residue. Rather, the authentic full-length hER β cDNA sequence encodes a polypeptide having 530 residues, the first 45 of which are not found in the previously known human sequence (Figure 4). The sequence appears to be quite

homologous to rat ER β ; however, this reading frame was not identified previously (Kuiper et al., *Proc.Natl.Acad.Sci.USA* **93**:5925, 1996). Furthermore, an optimal Kozak translation initiation sequence is found upstream of the newly discovered initiator methionine codon. A termination codon was identified 63 nucleotides upstream to the authentic ATG initiator codon

5 in the same reading frame.

The cDNA encoding authentic full-length hER β was cloned into pCDNA3 under the control of the CMV promoter; this expression vector was designated "long hER β " or hER β_L .

10 Synthesis of full-length hER β and truncated hER β

To examine the natural start site for translation of hER β , three plasmids were subjected to coupled transcription-translation, encoding hER β_T (with a synthetic upstream translation initiation sequence), hER β_L (with a synthetic upstream translation initiation sequence), and hER β_L containing 93 nucleotides of its native upstream sequence (the entire

15 sequence shown in Figure 3). The plasmids were transcribed and translated using the TNT T7 Coupled Reticulocyte Lysate System (Promega #L4610). Circular plasmid DNA was purified using Qiagen Maxi-Kit #12362. 2 μ g of the DNA was transcribed and translated in a single reaction in the presence of [³⁵S]-methionine (New England Nuclear, Boston MA). The translation products were resolved on a 10% SDS polyacrylamide gel and were visualized

20 by autoradiography (Figure 5).

The resulting translation products of both hER β_L products were of similar size (~63 kDa), and the hER β_T product was appropriately shorter (~56 KDa). This indicates that the initiator ATG most likely utilized *in vivo* is the ATG at position 94-96. Utilization

of a further upstream ATG is unlikely because of a termination codon in-frame with the presumed start site. Confirmation of the authentic start site is achieved by subjecting hER β polypeptides to aminoterminal sequencing.

5 Functional differences between full-length hER β and truncated hER β

The experiments described below were performed to evaluate the transcription activation properties of full-length hER β according to the present invention and to compare it with that of truncated hER β . hER β_L and hER β_T were expressed in parallel in different cell types and tested for their ability to transactivate reporter genes containing estrogen response
 10 elements (EREs). Alternatively, hER β_L and hER β_T may be expressed in host cells containing endogenous estrogen-responsive genes and the estrogen-mediated activation of the endogenous genes is measured.

(i) HepG2 Cells:

HepG2 cells (ATCC) were transfected in parallel with either pcDNA3-hER β_L
 15 or pcDNA3-hER β_T using the calcium phosphate co-precipitation method. Cells were co-transfected with a reporter plasmid containing a luciferase gene preceded by either an ERE upstream of the thymidine kinase (TK) basal promoter, or the TK basal promoter alone. Cells also received a plasmid encoding β -galactosidase under the control of an RSV promoter, which was used to correct for variation in DNA uptake. Five hours after transfection, cells
 20 were incubated with or without 10^{-6} M 17- β estradiol for 20 hours, after which cell extracts were prepared. Luciferase activity was measured by a chemiluminescent method using the Promega luciferase assay system, and β -galactosidase activity was measured by Galactolight

(Tropix, Inc., Bedford MA); luciferase activity was then normalized to β -galactosidase activity.

The results shown in Figure 6A indicate that, in the presence of estradiol, hER β_T caused a 2-fold stimulation of ERE activity. By contrast, hER β_L under the same
 5 conditions caused a 6-fold stimulation of ERE activity. Thus, hER β_L is about 3-fold more active than hER β_T in this circumstance.

In a separate experiment, HepG2 cells were transfected with hER β_L or hER β_T as above, but the reporter gene consisted of three copies of an NFkB binding site upstream of the TK basal promoter. Transfected cells were incubated with or without interleukin-1 β
 10 (IL-1 β) to activate NFkB and/or with estradiol prior to luciferase determination. The results shown in Figure 7 indicate that hER β_L was capable of attenuating the IL-1 β -mediated NFkB transcriptional activation (to an extent similar to that observed with hER α), while hER β_T exhibited no inhibitory activity.

(ii) Human endothelial cells:

15 HAECT-1 cells (a clonal immortalized human aortic endothelia cell line derived by infection with Ad5 ori-SV40 ts A209) were transfected with pcDNA3hER β_T or pcDNA3-hER β_L and ERE-luciferase plasmids by electroporation. After 4 hours, the cells were treated overnight with or without 100 nM 17- β estradiol prior to luciferase activity measurements. The results shown in Figure 8 indicate that hER β_L is 2-3 times more active
 20 than hER β_T in activating the ERE-reporter gene in the presence of estradiol. In independent experiments, cells transfected under identical conditions were monitored for their levels of estrogen receptors using a ligand binding assay. The results indicate that the increased activity of hER β_L relative to hER β_T is not due to an increase in receptor number or stability,

and, further, that the 2-3 fold increment measured in the above experiment may be an underestimate of the true transactivational capacity of hER β .

(iii) Yeast:

S. cerevisiae strain BJ2168 (Yeast Genetic Stock Center, Berkeley CA) was co-transformed with an ERE-LacZ reporter plasmid (designated YRpE2) and yeast vectors expressing either hER β_L or hER β_T under the control of the yeast triose phosphate isomerase promoter in the yeast pYX242 vector (R&D Systems, Minneapolis MN). Transformed cells were grown in selective medium for 24 hours, after which they were treated in the presence or absence of increasing concentrations of either 17- β estradiol or the phytoestrogen Genistein (Research Biochemical International, Natick MA) for 3 hours prior to determination of β -galactosidase activity. The dose-response results shown in Figure 9 indicate that the maximal level of estrogen-stimulated LacZ expression was 2-fold higher in hER β_L -transformed cells relative to hER β_T -transformed cells.

DNA, Vectors, and Expression Systems

Many conventional techniques in molecular biology, microbiology, and recombinant DNA, are used in practicing the present invention. See, for example, Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; *DNA Cloning: A Practical Approach*, Volumes I and II, 1985 (D.N. Glover ed.); *Oligonucleotide Synthesis*, 1984, (M.L. Gait ed.); *Nucleic Acid Hybridization*, 1985, (Hames and Higgins); *Transcription and Translation*, 1984 (Hames and Higgins eds.); *Animal Cell Culture*, 1986 (R.I. Freshney ed.); *Immobilized Cells and Enzymes*, 1986 (IRL Press); Perbal, 1984, *A Practical Guide to Molecular Cloning*; the

series, *Methods in Enzymology* (Academic Press, Inc.); *Gene Transfer Vectors for Mammalian Cells*, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory); and *Methods in Enzymology* Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively).

5 The present invention encompasses purified, isolated, nucleic acid sequences encoding hER β , including, e.g., the nucleotide sequence depicted in Figure 3 SEQ ID NO:1 and subfragments derived therefrom, including without limitation transcriptional activation-competent fragments. An "isolated" or "purified" nucleic acid is a nucleic acid or polypeptide that is removed from its original environment (for example, its natural
10 environment if it is naturally occurring). An isolated nucleic acid or polypeptide contains less than about 50%, preferably less than about 75%, and most preferably less than about 90%, of the cellular components with which it was originally associated.

A nucleic acid that is "derived from" an hER β sequence is a nucleic acid sequence that corresponds to a region of the sequence, sequences that are homologous or
15 complementary to the sequence, and "sequence-conservative variants" and "function-conservative variants". Sequence-conservative variants are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position. Function-conservative variants are those in which the amino acid sequence of hER β has been changed without altering the overall conformation and
20 transcriptional activation function of the hER β polypeptide, including, but not limited to, replacement of an amino acid with one having similar physico-chemical properties (such as, for example, acidic, basic, hydrophobic, and the like). A large number of candidate function-conservative hER β variants, as well as fragments of hER β that retain transcriptional

activation activity, can be prepared using routine recombinant DNA manipulations as well as random or site-directed mutagenesis techniques. Furthermore, hER β -derived variants or fragments that exhibit transcriptional activation activity can be identified using routine experimentation by employing the methods described herein, e.g., by co-expression with an appropriate reporter gene followed by measurement of reporter gene transcription in the presence and absence of an estrogen.

In another embodiment, the present invention encompasses isolated, purified, nucleic acids comprising nucleotides 94-229 of the sequence depicted in Figure 3, SEQ ID NO:1, which encode amino acids 1-45 of hER β , and sequence-conservative variants thereof.

The nucleic acids of the present invention include purine- and pyrimidine-containing polymers of any length, either polyribonucleotides or polydeoxyribonucleotides or mixed polyribo-polydeoxyribo nucleotides. This includes single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids, as well as "protein nucleic acids" (PNA) formed by conjugating bases to an amino acid backbone. This also includes nucleic acids containing modified bases.

The nucleic acids may be isolated directly from cells. Alternatively, PCR can be used to produce the nucleic acids of the invention, using either chemically synthesized strands or genomic material as templates. Primers used for PCR can be synthesized using the sequence information provided herein and can further be designed to introduce appropriate new restriction sites, if desirable, to facilitate incorporation into a given vector for recombinant expression.

The nucleic acids of the present invention may be flanked by natural regulatory sequences, or may be associated with heterologous sequences, including promoters,

enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5'- and 3'- noncoding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Nucleic acids may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators. PNAs are also included. The nucleic acid may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage. Furthermore, the nucleic acid sequences of the present invention may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.

The invention also provides nucleic acid vectors comprising hER β -encoding sequences or derivatives or fragments thereof. A large number of vectors, including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple cloning or protein expression. The encoded hER β -derived polypeptides may be expressed by using many known vectors, such as pUC plasmids, pET plasmids (Novagen, Inc., Madison, WI), or pRSET or pREP (Invitrogen, San Diego, CA), and many appropriate host cells, using methods disclosed or cited herein or otherwise known to those skilled in the

relevant art. The particular choice of vector/host is not critical to the practice of the invention.

Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes. The inserted hER β -encoding sequences may be synthesized by standard methods, isolated from natural sources, or prepared as hybrids, etc. Ligation of the hER β -encoding sequences to transcriptional regulatory elements and/or to other amino acid coding sequences may be achieved by known methods. Suitable host cells may be transformed/transfected/infected as appropriate by any suitable method including electroporation, CaCl₂ mediated DNA uptake, viral vector-mediated DNA delivery, fungal infection, microinjection, microprojectile, or other established methods.

Appropriate host cells included bacteria, archebacteria, fungi, especially yeast, and plant and animal cells, especially mammalian cells. Of particular interest are *E. coli*, *B. Subtilis*, *Saccharomyces cerevisiae*, *Saccharomyces carlsbergensis*, *Schizosaccharomyces pombe*, SF9 cells, C129 cells, 293 cells, *Neurospora*, and HepG2 cells, CHO cells, COS cells, HeLa cells, and immortalized mammalian myeloid and lymphoid cell lines. Preferred replication systems include M13, ColE1, SV40, baculovirus, lambda, adenovirus, and the like. A large number of transcription initiation and termination regulatory regions have been isolated and shown to be effective in the transcription and translation of heterologous proteins in the various hosts. Examples of these regions, methods of isolation, manner of manipulation, etc. are known in the art. Under appropriate expression conditions, host cells can be used as a source of recombinantly produced hER β -derived peptides and polypeptides.

Advantageously, vectors may also include a transcription regulatory element (i.e., a promoter) operably linked to the hER β portion. The promoter may optionally contain operator portions and/or ribosome binding sites. Non-limiting examples of bacterial promoters compatible with *E. coli* include: β -lactamase (penicillinase) promoter; lactose promoter; tryptophan (trp) promoter; arabinose BAD operon promoter; lambda-derived P_i promoter and N gene ribosome binding site; and the hybrid tac promoter derived from sequences of the trp and lac UV5 promoters. Non-limiting examples of yeast promoters include triose phosphate isomerase promoter, 3-phosphoglycerate kinase promoter, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, galactokinase (GAL1) promoter, galactose epimerase promoter, and alcohol dehydrogenase (ADH) promoter. Suitable promoters for mammalian cells include without limitation viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV). Mammalian cells may also require terminator sequences and poly A addition sequences and enhancer sequences which increase expression may also be included; sequences which cause amplification of the gene may also be desirable. Furthermore, sequences that facilitate secretion of the recombinant product from cells, including, but not limited to, bacteria, yeast, and animal cells, such as secretory signal sequences and/or prohormone pro region sequences, may also be included. These sequences are well described in the art.

Nucleic acids encoding hER β -derived polypeptides may also be introduced into cells by recombination events. For example, such a sequence can be introduced into a cell, and thereby effect homologous recombination at the site of an endogenous gene or a sequence with substantial identity to the gene. Other recombination-based methods such as

nonhomologous recombinations or deletion of endogenous genes by homologous recombination may also be used.

The nucleic acids of the present invention find use as templates for the recombinant production of hER β -derived peptides or polypeptides.

5

hER β -derived polypeptides

The present invention encompasses purified hER β -derived polypeptides comprising amino acids 1-45 of hER β and further comprising all or part of the amino acid sequence depicted in Figure 4, SEQ ID NO:2, and function-conservative variants thereof, i.e., variants that exhibit estrogen-induced transcriptional activation activity. Also encompassed by the invention are peptides comprising amino acids 1-45 of SEQ ID NO:2 and function-conservative variants thereof.

Nucleic acids comprising hER β -coding sequences can be used to direct the expression of hER β -derived polypeptides in intact cells or in cell-free translation systems.

The known genetic code, tailored if desired for more efficient expression in a given host organism, can be used to synthesize oligonucleotides encoding the desired amino acid sequences. The phosphoramidite solid support method of Matteucci *et al.*, 1981, *J. Am. Chem. Soc.* **103**:3185, the method of Yoo *et al.*, 1989, *J. Biol. Chem.* **764**:17078, or other well known methods can be used for such synthesis. The resulting oligonucleotides can be inserted into an appropriate vector and expressed in a compatible host organism.

The polypeptides of the present invention, including function-conservative variants of the disclosed hER β sequences, may be isolated from wild-type or mutant human cells, or from heterologous organisms or cells (including, but not limited to, bacteria, fungi,

insect, plant, and mammalian cells) into which an hER β -derived protein-coding sequence has been introduced and expressed. Furthermore, the polypeptides may be part of recombinant fusion proteins.

Polypeptides may be chemically synthesized by commercially available automated procedures, including, without limitation, exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, 1963, *J. Am. Chem. Soc.* 85:2149.

"Isolation" or "purification" of an hER β -derived polypeptide refers to the isolation of the polypeptide in a form that allows its transcriptional activation activity to be measured without interference by other components of the cell in which the polypeptide is expressed. Methods for polypeptide purification are well-known in the art, including, without limitation, preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. For some purposes, it is preferable to produce the polypeptide in a recombinant system in which the hER β -derived protein contains an additional sequence tag that facilitates purification, such as, but not limited to, a polyhistidine sequence. The polypeptide can then be purified from a crude lysate of the host cell by chromatography on an appropriate solid-phase matrix. Alternatively, antibodies produced against an hER β -derived protein or against peptides derived therefrom can be used as purification reagents. Other purification methods are possible.

The present invention also encompasses derivatives and homologues of hER β -encoded polypeptides. For some purposes, nucleic acid sequences encoding the peptides may

be altered by substitutions, additions, or deletions that provide for functionally equivalent molecules, i.e., function-conservative variants. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of similar properties, such as, for example, positively charged amino acids (arginine, lysine, and histidine);

5 negatively charged amino acids (aspartate and glutamate); polar neutral amino acids; and non-polar amino acids.

The isolated polypeptides may be modified by, for example, phosphorylation, sulfation, acylation, or other protein modifications. They may also be modified with a label capable of providing a detectable signal, either directly or indirectly, including, but not

10 limited to, radioisotopes and fluorescent compounds.

hER β -specific Antibodies

The present invention encompasses antibodies that specifically recognize hER β -derived peptides and polypeptides, including without limitation antibodies that recognize

15 hER β but not, e.g., hER α , and those that recognize hER β_L but not hER β_T . Such hER β -specific antibodies can be used conventionally, e.g., as diagnostic reagents or as reagents for purification of hER β -derived polypeptides. Other uses include immunocytochemical localization of hER β ; gel shift assays; and "pull-down" experiments to identify protein co-activators associated with hER β .

20 hER β -specific antibodies according to the present invention include polyclonal and monoclonal antibodies. The antibodies may be elicited in an animal host by immunization with hER β immunogenic components or may be formed by *in vitro* immunization (sensitization) of immune cells. The immunogenic components used to elicit

the production of antibodies may be isolated from any cell source or may be chemically synthesized. The antibodies may also be produced in recombinant systems programmed with appropriate antibody-encoding DNA. Alternatively, the antibodies may be constructed by biochemical reconstitution of purified heavy and light chains. The antibodies include hybrid

5 antibodies (i.e., containing two sets of heavy chain/light chain combinations, each of which recognizes a different antigen), chimeric antibodies (i.e., in which either the heavy chains, light chains, or both, are fusion proteins), and univalent antibodies (i.e., comprised of a heavy chain/light chain complex bound to the constant region of a second heavy chain). Also included are Fab fragments, including Fab' and F(ab)₂ fragments of antibodies. Methods for

10 the production of all of the above types of antibodies and derivatives are well-known in the art. For example, techniques for producing and processing polyclonal antisera are disclosed in Mayer and Walker, 1987, *Immunochemical Methods in Cell and Molecular Biology*, (Academic Press, London). The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell

15 fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., Schreier *et al.*, 1980, *Hybridoma Techniques*. Panels of monoclonal antibodies produced against hER β epitopes can be screened for various properties; i.e., for isotype, epitope affinity, etc.

Antibodies against hER β -derived immunogenic components can be used,

20 unlabeled or labeled by standard methods, as the basis for immunoassays. The particular label used will depend upon the type of immunoassay used. Examples of labels that can be used include but are not limited to radiolabels such as ³²P, ¹²⁵I, ³H and ¹⁴C; fluorescent labels such as fluorescein and its derivatives, rhodamine and its derivatives, dansyl and

umbelliferone; chemiluminescers such as luciferia and 2,3-dihydrophthal-azinediones; and enzymes such as horseradish peroxidase, alkaline phosphatase, lysozyme and glucose-6-phosphate dehydrogenase.

5 Applications

The methods and compositions of the present invention can be used to identify compounds that interact with hER β , either to activate or to inhibit its transcriptional activation function. Such compounds include, without limitation, co-activator proteins, as well as estrogens and other steroids, steroid-like molecules, or non-steroid-like molecules that act as
10 agonists or antagonists. Screening methods can also be used to identify tissue-specific estrogens.

Identification of hER β -interactive compounds can be achieved by cell-free or cell-based assays. In one set of embodiments, purified hER β is contacted with a labelled ligand, such as, e.g., 17- β estradiol, in the presence of test compounds to form test reactions,
15 and in the absence of test compounds to form control reactions. The labelled moiety may comprise a radiolabel (such as, e.g., ^3H or ^{125}I) or a fluorescent molecule. Incubation is allowed to proceed for a sufficient time and under appropriate conditions to achieve specific binding, after which binding of labelled estradiol to hER β is measured (by monitoring, e.g., radioactivity, fluorescence, or fluorescence polarization). In one embodiment, hER β
20 produced in *E. coli* (as described in Example 1 below) is adsorbed to the wells of a microtiter dish and incubated with [^3H]-17 β estradiol in the absence or presence of test compounds (see, e.g., Example 2 below). Alternatively, soluble receptor is incubated with the labelled ligand in the absence or presence of test compounds, and bound ligand is separated from free

ligand, either by filtration on glass fiber filters or by using dextran-coated charcoal. See, e.g., Hulme, ed., *Receptor-ligand Interactions: A Practical Approach*, IRL Press, NY, 1992).

Whole cell binding assays may also be used in which bound ligand is separated from free ligand by rinsing. Cells used in these assays may either contain endogenous receptor, or may overexpress the receptor subsequent to stable or transient transfection or infection of an hER β gene or cDNA. Non-limiting examples of suitable cells include COS cells, Hela cells, CHO cells, human umbilical vein endothelial cells (HUVEC), and yeast. Once a compound has been identified as an hER β -interactive compound by its binding activity, further *in vivo* and *in vitro* tests may be performed to determine the nature and extent of activity, i.e., as an agonist or antagonist (see below).

hER β -interactive compounds may also be identified using cell-based assays that measure transcriptional activation or suppression of endogenous or transfected estrogen-responsive genes. For example, agonists (such as, e.g., 17 β -estradiol) block interleukin-1 β induction of endogenous E-selectin in primary human umbilical vein endothelial cells (HUVEC) that express hER β . Antagonists (such as, e.g., ICI-182780) block the agonist activity of 17 β -estradiol. Non-limiting examples of other suitable endogenous estrogen-responsive promoter elements include those that regulate endothelin-1 (ET-1); HDL receptor (scavenger receptor type II); and enzymes involved in coagulation and fibrinolysis (such as, e.g., plasminogen activator inhibitor-1 and complement C3). Any promoter element that responds to estrogen may be used as an appropriate target, including, e.g., the NF κ B binding site or the apolipoprotein A1 gene enhancer sequence.

In one set of embodiments, appropriate host cells are transfected with an expression vector encoding hER β and the transfectants are incubated with or without estradiol

in the presence or absence of test compounds. hER β activity is assessed by measuring transcriptional activation of the target sequence. This may be achieved by detection of mRNA (using, e.g., Northern blot analysis) and/or by detection of the protein (using, e.g., immunoassays or functional assays). If activation of the target sequence initiates a biochemical cascade, downstream biological events may also be measured to quantify hER β activity. hER β -interactive compounds are identified as those that positively or negatively influence target sequence activation.

In another set of embodiments, appropriate host cells (preferably, bacterial or yeast cells) are co-transfected with an expression vector encoding hER β and a reporter plasmid containing a reporter gene downstream of one or more estrogen response elements (EREs). Transfected cells are incubated with or without estradiol in the presence or absence of test compounds, after which hER β activity is determined by measuring expression of the reporter gene. In a preferred embodiment, hER β activity is monitored visually. Non-limiting examples of suitable reporter genes include luciferase, chloramphenicol acetyl transferase (CAT), and green fluorescence protein.

Preferably, the methods of the present invention are adapted to a high-throughput screen, allowing a multiplicity of compounds to be tested in a single assay. Candidate estrogens and estrogen-like compounds include without limitation diethylstilbesterol, genistein, and estrone. Other hER β -interactive compounds may be found in, for example, natural product libraries, fermentation libraries (encompassing plants and microorganisms), combinatorial libraries, compound files, and synthetic compound libraries.

For example, synthetic compound libraries are commercially available from Maybridge Chemical Co. (Trevillet, Cornwall, UK), Comgenex (Princeton, NJ), Brandon Associates

(Merrimack, NH), and Microsource (New Milford, CT). A rare chemical library is available from Aldrich Chemical Company, Inc. (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available from, for example, Pan Laboratories (Bothell, WA) or MycoSearch (NC), or are readily producible.

5 Additionally, natural and synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means (Blondelle et al., *TibTech* 14:60, 1996). hER β binding assays according to the present invention are advantageous in accommodating many different types of solvents and thus allowing the testing of compounds from many sources.

10 Compounds identified as hER β agonists or antagonists using the methods of the present invention may be modified to enhance potency, efficacy, uptake, stability, and suitability for use in therapeutic applications, etc. These modifications are achieved and tested using methods well-known in the art.

15 **Description of the Preferred Embodiments**

The following examples are intended to illustrate the present invention without limitation.

20 **Example 1: High-level Expression of Human hER β in *E. coli***

Human hER β according to the present invention is overexpressed in *E. coli* strain BL21(DE3) using, for example, the pET15B vector. A 10-ml overnight culture is used to inoculate 1 liter LB medium containing 100 μ g/ml ampicillin. Cultures are grown at 37°C

and then induced by the addition of 1 mM IPTG. After an additional incubation for 2h at 25°C, cells are harvested by centrifugation at 10,000 X G for 30 minutes and resuspended in 100 ml of a buffer containing 50 mM Tris-HCl, pH 7.4 -150 mM NaCl. Cells are lysed using a French press, and insoluble material is pelleted by centrifugation. The supernatant
5 solution is recovered and stored at -70°C.

Example 2: Estrogen Receptor- β Ligand Binding Assay

For determining the ability of a particular compound to bind hER β , 100 μ l of
10 the receptor preparation described in Example 1 above, diluted in assay buffer (Dulbecco's phosphate buffered saline (Gibco #14200-075) supplemented with 1 mM EDTA), is added to each well of a high-binding masked microtiter plate (Wallac #1450-511, Gaithersburg MD). 10 μ l of test compound (or vehicle) and 10 μ l of [3 H]-17 β -estradiol are added to each well, and the plate is incubated at room temperature for 4-6 hours. Unbound material is aspirated,
15 and the plate is washed three times with 300 μ l of assay buffer. Then, 150 μ l of scintillation cocktail (Optiphase Supermix, Wallac #1200-439) is added per well, and the plate is sealed and agitated for at least 5 min. Bound radioactivity is measured by scintillation counting.

Test compounds are initially tested at a concentration of 1.5 μ g/ml (approximately 5 μ M for a compound having a molecular mass of 300). Positive compounds
20 are then re-tested at a number of different concentrations to determine the IC₅₀.

Data are expressed as percent inhibition of specific binding. Exploratory data analysis (EDA) is performed on raw data to check for non-normality and non-homogeneity

of variance. The maximum likelihood Box-Cox transformation, which maximizes the normality, homogeneity of variance, and goodness of fit of the data, is then obtained. Based on the result, the appropriate transformation of the data (no transformation, square root transformation, or logarithmic transformation) is used for model fitting. The Huber M-estimator is used to down weight any outlying transformed observations for analysis of variance and dose-response curve fitting.

For ANOVA, multiple comparisons LSD p-values are computed. Re-transformed summary statistics (mean, s.d, s.e.m.) are obtained for each treatment group.

For dose-response curve fitting, a four parameter logistic model on the transformed, weighted data are fit. The four parameters are min, max, slope, and ED50, where ED50 is defined as the dose which corresponds to midway between the estimated max and min. All of the parameters and confidence intervals are re-transformed back to the original units of the data. A further transformation into percent inhibition (using estimated min and max) is performed.

Using this assay, the following values were obtained for reference compounds:

| | <u>IC₅₀</u> | <u>95% confidence limits</u> |
|-----------------------|------------------------|------------------------------|
| 17 β -estradiol | 6.7 nM | 6 - 7.5 nM |
| diethylstilbestrol | 21 nM | 14 - 31 nM |
| genistein | 1.6 nM | 1.4 - 1.8 nM |

All patents, applications, articles, publications, and test methods mentioned above are hereby incorporated by reference.

Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. Such obvious variations are within
5 the full intended scope of the appended claims.

Claims:

- 1 1. An isolated nucleic acid comprising the sequence depicted in Figure 1,
2 SEQ ID NO:1.
- 1 2. A nucleic acid as defined in claim 1, wherein said nucleic acid is DNA.
- 1 3. A nucleic acid as defined in claim 1, wherein said nucleic acid is RNA.
- 1 4. A recombinant DNA vector comprising a sequence as defined in claim
2 1.
- 1 5. A recombinant DNA vector comprising a sequence as defined in claim 1
2 operably linked to a transcription regulatory element.
- 1 6. A cell comprising a DNA vector as defined in claim 5, wherein said cell
2 is selected from the group consisting of bacterial, fungal, plant, insect, and mammalian cells.
- 1 7. A method for producing a polypeptide, said method comprising incubating
2 a cell as defined in claim 6 under conditions that permit expression of one or more
3 polypeptides encoded by said nucleic acid.
- 1 8. A method as defined in claim 7, further comprising:

- 2 (a) harvesting said incubated cells to produce a cell fraction and a medium
3 fraction; and
4 (b) recovering said one or more polypeptides from said cell fraction, said
5 medium fraction, or both.

1 9. A purified isolated nucleic acid encoding the amino acid sequence depicted
2 in Figure 1 SEQ ID NO:2.

1 10. A nucleic acid as defined in claim 9, wherein said nucleic acid is DNA.

1 11. A nucleic acid as defined in claim 9, wherein said nucleic acid is RNA.

1 12. A recombinant DNA vector comprising a sequence as defined in claim 9.

1 13. A recombinant DNA vector comprising a sequence as defined in claim 9
2 operably linked to a transcription regulatory element.

1 14. A cell comprising a DNA vector as defined in claim 13, wherein said cell
2 is selected from the group consisting of bacterial, fungal, plant, insect, and mammalian cells.

1 15. A method for producing a polypeptide, said method comprising incubating
2 a cell as defined in claim 14 under conditions that permit expression of one or more
3 polypeptides encoded by said nucleic acid.

1 16. A method as defined in claim 15, further comprising:

2 (a) harvesting said incubated cells to produce a cell fraction and a medium
3 fraction; and

4 (b) recovering said one or more polypeptides from said cell fraction, said
5 medium fraction, or both.

6 17. A purified polypeptide comprising a sequence selected from the group
7 consisting of the sequence depicted in Figure 1 SEQ ID NO:2 and function-conservative
8 variants thereof.

9 18. A purified polypeptide comprising amino acids 1-45 of the sequence depicted
10 in Figure 1 SEQ ID NO:2.

1 19. A method for identifying hER β -interactive compounds, said method
2 comprising:

3 (a) contacting purified hER β with a labelled ligand in the presence of test
4 compounds, to form test reactions, and in the absence of test compounds, to form control
5 reactions;

- 6 (b) incubating said test and control reactions under appropriate conditions
7 to achieve equilibrium binding of said labelled ligand to hER β ;
8 (c) determining the level of binding of said labelled ligand to hER β in said
9 test and control cultures; and
10 (d) identifying as a hER β -interactive compound any compound that reduces
11 the binding of said labelled ligand to hER β .

1 20. A method as defined in claim 19, wherein said ligand is 17- β estradiol.

1 21. A method as defined in claim 19, wherein said hER β -interactive
2 compound is an agonist.

1 22. A method as defined in claim 19, wherein said hER β -interactive
2 compound is an antagonist.

3 23. An antibody that specifically recognizes hER β .


ABSTRACT OF THE DISCLOSURE

The present invention provides isolated nucleic acids encoding full-length human estrogen receptor- β (hER β), which comprises 530 amino acids. The invention also provides isolated hER β polypeptides and hER β -reactive antibodies, including those that specifically recognize amino acids 1-45 of hER β . The invention also encompasses methods for identifying hER β -interactive compounds, including agonists, antagonists, and co-activators.

FIGURE 1

PCR Cloning of the Human ER β

Human testis RNA was reverse transcribed using Oligo dT. The resulted transcript was used for PCR with Oligonucleotides (red arrows) designed as follows:



The PCR product was cloned in the Hind III and XbaI sites of the Eukaryotic expression vector pcDNA III.

FIGURE 2

Human ER β cDNA






Fig 2

CAGOCATTATACTTGOCCACGAATCTTTGAGAACATTATAATGACCTTTGTGCOCTCTTCT 60
 TGCAAGGTGTTTTCTCAGCTGCTATCTCAAGACATGGATATAAAAACTCACCATCTAGC 120
 CTTAATTCTOCTTCTOCTCTACAACCTGCAGTCAATOCATCTTAOCCCTGGAGCACGGCTCC 180
 ATATACATAOCTTCTOCTCCATGTAGACAGCCACCATGAATATOCAGCCATGACATTCTAT 240
 AGCOCTGCTGTGATGAATTACAGCATTCCAGCAATGTCACTAACTTGAAGGTGGGOCT 300
 GGTGGCAGAACACAAGOOCAAATGTGTTGTGGCAACAOCTGGGCAOCTTTCTOCTTTA 360
 GTGGTGCATOGOCAGTTATCACATCTGTATGOGGAOCTCAAAAGAGTCCCTGGTGTGAA 420
 GCAAGATOGCTAGAACACACCTTACCTGTAAACAGAGAGACACTGAAAAGGAAGGTTAGT 480
 GGGAAOOGTTGCGCCAGOOCTGTTACTGGTCCAGGTTCAAAGAGGGATGCTCACTTCTGC 540
 GCTGTCTGCAGOGATTACGCATCGGGATATCACTATGGAGTCTGGTOGTGTGAAGGATGT 600
 AAGGCCTTTTTTAAAAAGAAGCATTCAAGGACATAATGATTATATTTGTCCAGCTACAAAT 660
 CAGTGTACAATCGATAAAAAOOGGOGCAAGAGCTGOCAGGOCTGCOGACTTCOGAAGTGT 720
 TAOGAAGTGGAATGGTGAAGTGTGGCTOOOOGGAGAGAGAGATGTGGGTACCGOCTTGTG 780
 OGGAGACAGAGAAGTGCOGACGAGCAGCTGCACTGTGCOGGCAAGGCOCAAGAGAAGTGGC 840
 GGCAOOGOGOOOOGAGTGOGGGAGCTGCTGCTGGACGOOCTGAGOOOOGAGCAGCTAGTG 900
 CTCAOOCTOCTGGAGGCTGAGOOOGOOOCATGTGCTGATCAGOOOGOOOCAGTGOGOOCTTC 960
 ACOGAGGOCTOCATGATGATGTOOCTGAOCCAAGTTGGOOGACAAGGAGTTGGTACACATG 1020
 ATCAGCTGGGCOCAAGAAGATTCCOOGGCTTTGTGGAGCTCAGCCTGTTGACCAAGTGOGG 1080
 CTCTTGGAGAGCTGTTGGATGGAGGTGTTAATGATGGGGCTGATGTGGOGCTCAATTGAC 1140
 CACCCOOGGAAGCTCATCTTTGCTOCAGATCTTGTTCTGGACAGGGATGAGGGGAAATGC 1200
 GTAGAAGGAATTCTGGAAATCTTTGACATGCTOCTGGCAACTACTTCAAGGTTTCGAGAG 1260
 TTAACAACTCCAACACAAAGAATATCTCTGTGTCAAGGOCATGATCCTGCTCAATTCCAGT 1320
 ATGTAAOCTCTGGTCAAGOGACCCAGGATGCTGACAGCAGCOGGAAGCTGGCTCACTTG 1380
 CTGAAOOGOGTGACOGATGCTTTGGTTTGGGTGATTGCCAAGAGOGGCATCTOCTOCCAG 1440
 CAGCAATOCATGCGOCTGGCTAAOCTOCTGATGCTOCTGTCCACGTCAGGCATGOGAGT 1500
 AACAAGGGCATGGAACATCTGCTCAACATGAAGTGCAAAAAATGTGGTCCAGTGTATGAC 1560
 CTGCTGCTGGAGATGCTGAATGCOCAOGTGCTTCOGGGGTGCAAGTOCTOCATCAOGGGG 1620
 TOOGAGTGCAGOOOOGGAGAGGACAGTAAAGCAAAGAGGGCTOCCAGAAOCCACAGTCT 1680
 CAGTGA 1686



763

Fig 5



09499999 100000

F766



Transactivation of ERE reporter By ER β_L and ER β_T In HepG2 cells. Luciferase reporter constructs (0.5 ug) containing either [A] the estrogen receptor DNA response element upstream of the TK basal promoter (ERE TK.LUC) or [B] the TK basal promoter alone (TK.LUC) were transiently transfected into HepG2 cells by the calcium phosphate coprecipitation method. Each construct was cotransfected with the ER expression vector (0.25 ug) indicated and the RSV- β -galactosidase plasmid (0.5 ug) to correct for variation in DNA uptake. Luciferase activity was normalized to β -galactosidase enzymatic activity.







Fig 7 Luciferase reporter constructs (0.5 μ g) containing either [A] 3 copies of an NF κ B binding site upstream of the TK basal promoter (3X-NF κ B TK.LUC) or [B] the TK basal promoter construct alone (TK.LUC) were transiently cotransfected into HepG2 cells by the calcium phosphate coprecipitation method. Each construct was cotransfected with the ER expression vector indicated and the plasmid RSV- β -galactosidase (0.5 μ g) to correct for variation in DNA uptake. Percent luciferase activity values represent Luc: β -galactosidase enzymatic activity ratios relative to a value of 100% designated for the IL-1 β treated samples and are presented as mean \pm S.E..

768



Transactivation of ERE reporter by ERβ_T and ERβ_L in HAECT-1 cells. Luciferase reporter constructs (20 μg) containing either the estrogen receptor DNA response element upstream of the TK basal promoter (ERE TK.LUC) or the TK basal promoter (TK.Luc) were transiently transfected into HAECT-1 cells (4x10⁶) with 5 μg of ER expression vector by electroporation. Cells were plated into 48 wells of a 96-well plate, rested for 4h, and treated overnight as indicated prior to luciferase determination. ERE TK.LUC values were normalized to TK.LUC values and are presented as mean ± S.E. (n=4).

K269



Transcriptional activity of hERβ_T and hERβ_L in yeast. Yeast cells (BJ2168) were cotransformed with an ERE-LacZ reporter (YRpE2) and either a yeast vector (pYX242) expressing hERβ_T or hERβ_L. Transformed cells were grown in selective medium for 24 h at 30°C. Cells were treated with 17-β estradiol or genestein, at the indicated concentrations, for 3 h and then assayed for β-galactosidase activity.

EXPRESS MAIL CERTIFICATE

Date

Label No.

10/29/99 595862917
I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

File No. 0646/1D205-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ramesh A. BHAT, et al.

For: NOVEL HUMAN ESTROGEN RECEPTOR B

ASSOCIATE POWER OF ATTORNEY

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

The undersigned attorney of record in the above-identified application hereby appoints:

Paul F. Fehlner (No. 35,135)
Phone: (212) 527-7700
Fax: (212) 753-6237

of Darby & Darby, P. C., located at 805 Third Avenue, New York, New York 10022, as associate attorney with full power to prosecute said application, and to transact all business in the United States Patent and Trademark Office in connection therewith.

Please forward all communications to:

Paul F. Fehlner, Ph.D.
Darby & Darby P.C.
805 Third Avenue
New York, New York 10022

Michael J. Sweedler
Reg. No. 19,937

Reg. No. 19,937

**DECLARATION
AND POWER OF ATTORNEY
Original Application**

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor if only one name is listed at 1 below, or a joint inventor if plural inventors are named below, of the invention entitled:

NOVEL HUMAN ESTROGEN RECEPTOR-BETA

which is described and claimed in:

☐ the attached specification or ☒ the specification in application
Serial No. 08/906,365, filed August 5, 1997
(for declaration not accompanying appl.)

that I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application, that I acknowledge my duty to disclose information of which I am aware which is material to patentability in accordance with 37 CFR §1.56. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim the priority benefits under 35 U.S.C. 119 of any application(s) for patent or inventor's certificate listed below. All foreign applications for patent or inventor's certificate on this invention filed by me or my legal representatives or assigns prior to the application(s) of which priority is claimed are also identified below.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

| <u>COUNTRY</u> | <u>APPLICATION NO.</u> | <u>DATE OF FILING</u> |
|----------------|------------------------|-----------------------|
|----------------|------------------------|-----------------------|

**ALL FOREIGN APPLICATIONS, IF ANY, FILED PRIOR
TO THE APPLICATION(S) OF WHICH PRIORITY IS CLAIMED**

COUNTRY APPLICATION NO. DATE OF FILING

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agents(s) to prosecute this application and transact all business in the Patent and Trademark office connected therewith: Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Harold E. Wurst #22,183, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen #19,407, Henry Sternberg #22,408, Robert A. Green #28,301, Peter C. Schechter #31,662, Robert Schaffer #31,194, David R. Francescani #25,159, Robert C. Sullivan, Jr. #30,499, Ira J. Levy #35,587, Joseph R. Robinson #33,448

all of the firm of DARBY & DARBY P.C., 805 Third Avenue, New York, NY 10022

and Egon E. Berg #21,117, Steven H. Flynn # 29,639, Adley F. Mandel #26,942, Ronald W. Alice #27,609, Gale F. Matthews #32,269, Milagros A. Cepeda #33,365, Alan M. Gordon #30,637, Elizabeth M. Barnhard #31,088, Andrea C. Walsh # 34,988, and Darryl L. Webster #34,276

all of AMERICAN HOME PRODUCTS CORPORATION, Patent Law Department 2B, One Campus Drive, Parsippany NJ 07054

SEND CORRESPONDENCE TO: DIRECT TELEPHONE CALLS TO:

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

Joseph R. Robinson

212-527-7700

FULL NAME AND RESIDENCE OF INVENTOR 1

LAST NAME: BHAT FIRST NAME: Ramesh MIDDLE NAME: A.

CITY: King of Prussia STATE OR FOREIGN COUNTRY: Pennsylvania COUNTRY OF CITIZENSHIP: *INDIA*

POST OFFICE ADDRESS: 738 Champlain Drive CITY: King of Prussia STATE OR COUNTRY: Pennsylvania ZIP CODE: 19406

FULL NAME AND RESIDENCE OF INVENTOR 2

LAST NAME: HENDERSON FIRST NAME: Ruth MIDDLE NAME:

CITY: Swarthmore STATE OR FOREIGN COUNTRY: Pennsylvania COUNTRY OF CITIZENSHIP: *United States of America*

POST OFFICE ADDRESS: 1414 Conway Drive CITY: Swarthmore STATE OR COUNTRY: Pennsylvania ZIP CODE: 19081

FULL NAME AND RESIDENCE OF INVENTOR 3

LAST NAME: HSIAO FIRST NAME: Chulai MIDDLE NAME:
CITY: Wilmington STATE OR FOREIGN COUNTRY: Delaware COUNTRY OF CITIZENSHIP: *United State of America*
POST OFFICE ADDRESS: 1907 Harwyn Road CITY: Wilmington STATE OR COUNTRY: Delaware ZIP CODE: 19810

FULL NAME AND RESIDENCE OF INVENTOR 4

LAST NAME: KARATHANASIS FIRST NAME: Sotirios MIDDLE NAME: K.
CITY: Berwyn STATE OR FOREIGN COUNTRY: Pennsylvania COUNTRY OF CITIZENSHIP: *GREEK*
POST OFFICE ADDRESS: 862 Old State Road CITY: Berwyn STATE OR COUNTRY: Pennsylvania ZIP CODE: 19312-1443

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1: *Ramesh A. Bhat* DATED: 2-20-1998
Ramesh A. BHAT

SIGNATURE OF INVENTOR 2: *Ruth Henderson* DATED: 2-20-98
Ruth HENDERSON

SIGNATURE OF INVENTOR 3: *Chulai Hsiao* DATED: 2-20-98
Chulai HSIAO

SIGNATURE OF INVENTOR 4: *Sotirios A. Karathanasis* DATED: 2-20-98
Sotirios A. Karathanasis